Evidence map›Paper›PMID 29327172›Full record

ArticleJournal of neuro-oncology2018

Identifying candidates for gamma knife radiosurgery among elderly patients with brain metastases.

Tae Hoon Roh, Mi Sun Choi, Namkyu You, Donghwan Jeong, Ae Hwa Jang, Mi Ra Seo, Sang Ryul Lee, Se-Hyuk Kim

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Tae Hoon RohGamma Knife Center, Department of Neurosurgery, Ajou University School of Medicine, 164 World Cup-ro, Yeongtong-Gu, Suwon, 16499, South Korea.
Mi Sun ChoiGamma Knife Center, Department of Neurosurgery, Ajou University School of Medicine, 164 World Cup-ro, Yeongtong-Gu, Suwon, 16499, South Korea.
Namkyu YouGamma Knife Center, Department of Neurosurgery, Ajou University School of Medicine, 164 World Cup-ro, Yeongtong-Gu, Suwon, 16499, South Korea.
Donghwan JeongGamma Knife Center, Department of Neurosurgery, Ajou University School of Medicine, 164 World Cup-ro, Yeongtong-Gu, Suwon, 16499, South Korea.
Ae Hwa JangGamma Knife Center, Department of Neurosurgery, Ajou University School of Medicine, 164 World Cup-ro, Yeongtong-Gu, Suwon, 16499, South Korea.
Mi Ra SeoGamma Knife Center, Department of Neurosurgery, Ajou University School of Medicine, 164 World Cup-ro, Yeongtong-Gu, Suwon, 16499, South Korea.
Sang Ryul LeeGamma Knife Center, Department of Neurosurgery, Ajou University School of Medicine, 164 World Cup-ro, Yeongtong-Gu, Suwon, 16499, South Korea. sangryul79@gmail.com.
Se-Hyuk KimGamma Knife Center, Department of Neurosurgery, Ajou University School of Medicine, 164 World Cup-ro, Yeongtong-Gu, Suwon, 16499, South Korea. nsksh@ajou.ac.kr.
Ajou University · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the outcomes of gamma knife radiosurgery (GKRS) for elderly patients (≥ 65 years) with brain metastases, and identified survival-associated factors. We retrospectively analyzed data from 115 patients treated with GKRS for 1-15 brain metastases. The median patient age was 72 years; most primary tumors were pulmonary (n = 83). The mean lesion volume was 2.1 ± 4.8 mL. A mean dose of 19.3 Gy was delivered to the mean 63.9% isodose line. The median overall survival (OS) was 5.3 months (95% confidence interval [CI] 3.5-7.1). During follow-up (median, 5.1 months), 91 patients died of primary cancer progression while 1 died of unknown causes. The 6- and 12-month local control rates were 94.9 and 88.1%, respectively. On multivariate analysis, female sex (p = 0.005, hazard ratio [HR] 0.533, 95% CI 0.343-0.827) and a controlled primary tumor (p < 0.001, HR 0.328, 95% CI 0.180-0.596) were significantly favorable prognostic factors. Of non-small cell lung cancer patients with EGFR mutations, 76.5% were women (p = 0.005). The median OS of EGFR-mutant and EGFR-wildtype patients were 19.1 and 4.7 months, respectively (p = 0.080). Brain metastases < 3 mL showed better local control rates after GKRS (p = 0.005). GKRS produces favorable outcomes in women with brain metastases who are ≥ 65 years and have controlled primary tumors. Such patients are therefore suitable candidates for GKRS.

Indexed as

RadiosurgeryAgedAged, 80 and overAge FactorsBrain NeoplasmsErbB ReceptorsFemaleFollow-Up StudiesHumansMaleMutationNeoplasm Recurrence, LocalPatient SelectionRetrospective StudiesSurvival AnalysisTreatment OutcomeEGFR protein, humanErbB ReceptorsAgeMetastasisRadiosurgerySurvival

Identifiers

PMID29327172
OpenAlexW2783847742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.